The present invention relates to a T-cell receptor comprising: a) an alpha chain comprising an amino acid sequence as set forth in SEQ ID No.1 or a functional equivalent thereof; and/or b) a beta chain comprising an amino acid sequence as set forth in SEQ ID No.2 or a functional equivalent thereof; as well as uses thereof including in the treatment of an EBV+ tumour.